# NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Source: https://onco.cc/trials/nct05023486/  
OnCo record `nct05023486` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of NP-G2-044 Monotherapy in advanced solid tumours, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05023486 by Novita Pharmaceuticals, Inc., with 121 participants enrolled, started 2021-12-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: NP-G2-044 Monotherapy, Anti-PD-1 Therapy and NP-G2-044 Combination therapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05023486
- Phase: 1/2
- Setting: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
- Sponsor: Novita Pharmaceuticals, Inc.
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT05023486: https://clinicaltrials.gov/study/NCT05023486

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05023486.json